Species distribution and in vitro susceptibility of Candida bloodstream isolates to six new and current antifungal agents in a Turkish tertiary care military hospital, recovered through 2001 and 2006

Military Medicine

Volumn 174, Issue 8, 2009, Pages 860-865

  Saracli, Mehmet A ^a   Gumral, Ramazan ^b   Gul, Hanefi C ^a   Gonlum, Ahmet ^a   Yildiran, Sinasi T ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b Maresal Cakmak Military Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

ADULT; ARTICLE; BLOOD; CANDIDA; CANDIDIASIS; DRUG EFFECT; FEMALE; HUMAN; IN VITRO STUDY; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; PUBLIC HOSPITAL; STATISTICS; TURKEY (REPUBLIC);

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; FEMALE; HOSPITALS, MILITARY; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; TURKEY;

EID: 77949366905     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.7205/MILMED-D-04-7808     Document Type: Article

References (27)

1. Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-63.
2. Kao AS, Brandt ME, Pruitt WR, et al: The epidemiology of candidemia in two United States cities: result of a population-based active surveillance. Clin Infect Dis 1999;29:1164-70.
3. Marchetti O, Bille J, Fluckiger U, et al: Fungal infection network of Switzerland. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004;38:311-20.
4. Diekema DJ, Messer SA, Brueggemann AB, et al: Epidemiology of candidemia: 3-year results from the emerging infection and epidemiology of Iowa organism study. J Clin Microbiol 2002;40:1298-302.
5. Richet H, Roux P, Des Champs C, Esnault Y, Andremont A; French Candidemia Study Group: Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect 2002;8:405-12.
6. Trick WE, Fridkin SK, Edwards JR, et al: Secular trend of hospitalacquired candidemia among intensive care unit patients in the United Stales during 1989-1999. Clin Infect Dis 2002;35:627-30.
7. Tortorano AM, Peman J, Bernhardt H, et al: Epidemiology of candidemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004;23:317-22.
8. Sutton DA, Fothergill AW, Rinaldi MG (eds) : Guide to Clinically Significant Fungi, pp 88-113. Baltimore, Williams and Wilkins, 1998.
9. NCCLS: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Second Edition: Approved Standard M27-A2, pp 1-30. Edited by Pfaller MA, Chaturvedi V, Espinel-Ingroff A, et al. Villanova, PA, 2002.
10. Nguyen MH, Clancy CJ, Yu VL, et al: Do in vitro susceplibility data predict the microbial response to Amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998;177:425-30.
11. Pfaller MA, Diekema DJ, Rex JH, et al: Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006;44:819-26.
12. Pfaller MA, Diekema DJ, Gibbs DL, et al: Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008;46:842-9.
13. Archimedes da Matta D, Paula de Almedia L, Machado AM, et al: Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drags: results of a multicenter study conducted in Sao Paulo, Brazil, 1995-2003. Diagn Microbiol Infect Dis 2007;57:399-404.
14. Cuence-Estrella M, Rodriguez D, Almirante B, et al: In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005;55:194-9.
15. Lee JS, Shin JH, Lee K, et al: Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea. Yonsei Med J 2007: 48: 779-86.
16. Bakir M, Cerikcioglu N, Barton R, Yagci A: Epidemiology of candidemia in a Turkish tertiary care hospital. APMIS 2006;114:601-10.
17. Almirante B, Rodriguez D, Cuenca-Estrella M, et al: Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006;44:1681-5.
18. Hajjeh RA, Sofair AN, Harrison LH, et al: Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004;42:1519-27.
19. Pfaller MA, Messer SA, Boyken L, et al: In vitro activities of voriconazole, posaconazole, and fluconazole against 4, 169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004;48:201-5.
20. Pfaller MA, Boyken L, Hollis RJ, et al: In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9, 359 isolates tested by Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol 2005;43:3807-10.
21. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al: Antifungal susceptibility survey of 2, 000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47:3149-54.
22. Heck R, Dietz A, Hof H: In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother 2007;59:767-71.
23. Sóczó G, Kardos G, McNicholas PM, et al: Posaconazole susceptibility testing against Candida species: comparison of broth microdilution and E-test methods. Mycoses 2007;50:178-82.
24. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al: Head-to-head comparison of the activities of currently available antifungal agents against 3, 378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006;50:917-21.
25. Uzun O, Arikan S, Kocagoz S, et al: Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish university hospital and effect of time of reading. Diagn Microbiol Infect Dis 2000;38:101-7.
26. Arikan S, Sancak B, Hascelik G: In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital. Med Mycol 2005;43:171-8.
27. Wanger A, Mills K, Nelson PW, Rex JH: Comparison of E-test and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin-resistant Candida isolates. Antimicrob Agents Chemother 1995;39:2520-2.